Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
Authors:
Open Access
- 11 August 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (13) , 4440-4451
Abstract
Purpose: The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [177Lu]Lu-NeoB are administered to healthy female and male mice. Methods: Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [175Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [177Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was determined. For this, histopathological and blood analyses were performed. To correlate the observed toxicity to absorbed dose, we also performed extensive biodistribution and dosimetry studies. Results: The biodistribution study showed the highest absorbed doses in GRPR-expressing pancreas, the liver, and the kidneys (the main organs of excretion). Both control groups and almost all animals of treatment group 1 did not show any treatment-related toxicological effects. Despite the high absorbed doses, no clear microscopic signs of toxicity were found in the pancreas and the liver. Histological analysis indicated kidney damage in the form of hydronephrosis and nephropathy in treatment groups 2 and 3 that were sacrificed at the early and late time point. In the same groups, increased blood urea nitrogen levels were found. Conclusion: In general, repeated administration of [177Lu]Lu-NeoB was tolerated. The most significant radiotoxic effects were found in the kidneys, similar to other clinically applied radioligands. The results of this study underline the potential of [177Lu]Lu-NeoB as a promising option for clinical therapy.Keywords
Funding Information
- Advanced Accelerator Applications
This publication has 31 references indexed in Scilit:
- Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATECancer Biotherapy and Radiopharmaceuticals, 2012
- RADAR Realistic Animal Model Series for Dose AssessmentJournal of Nuclear Medicine, 2010
- Tumor Imaging and Therapy Using Radiolabeled Somatostatin AnaloguesAccounts of Chemical Research, 2009
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Why Are Chronic Kidney Disease Patients Anorexic and What Can Be Done About It?Seminars in Nephrology, 2009
- Mouse S-Factors Based on Monte Carlo Simulations in the Anatomical Realistic Moby Phantom for Internal DosimetryCancer Biotherapy and Radiopharmaceuticals, 2007
- Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapyAnnals of Oncology, 2007
- Ovarian function preservation in the cancer patientFertility and Sterility, 2004
- Radiation nephropathySeminars in Nephrology, 2003